Precisely, vaccination with a low dose of native Melan-A26−35 peptide together with IFA and CpG-B induced CD8 T-cells with higher TCR binding avidity and stronger tumor reactivity compared to vaccination with the analog Melan-A26−35 A27L peptide (8, 34). Here, CD8A is linked to neoplasm.